Senior Research Scientist
Pediatric Hematology & Oncology
Dr. Luke J. Whitesell, MD
|
|
Give Review
Dr. Luke J. Whitesell practices Pediatric Hematology & Oncology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care Luke J. Whitesell has written publications. He has 50 publications published with PubMed. The lastest paper is: 'Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice.'
Publications
- HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
- Biomimetic Kinetic Resolution: Highly Enantio- and Diastereoselective Transfer Hydrogenation of Aglain Ketones To Access Flavagline Natural Products.
- Structure-Activity Relationships for Withanolides as Inducers of the Cellular Heat-Shock Response.
- Fitness trade-offs restrict the evolution of resistance to amphotericin B.
- Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
- Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.
- Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state.
- Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition.
- An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 tra...
- Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
- ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicans.
- Using the Heat-Shock Response To Discover Anticancer Compounds that Target Protein Homeostasis.
- Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transforma...
- Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration.
- Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line.
- Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.
- Two cases of pediatric neuroblastoma with tumor thrombus in the inferior vena cava.
- Isolation, optimization of production and structure-activity relationship studies of monocillin I, the cytotoxic constituent of Paraphaeosphaeria quadriseptata.
- Cytotoxic constituents of Aspergillus terreus from the rhizosphere of Opuntia versicolor of the Sonoran Desert.
- 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera.
- The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways.
- Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES.
- A new dihydroxanthenone from a plant-associated strain of the fungus Chaetomium globosum demonstrates anticancer activity.
- HSP90: a rising star on the horizon of anticancer targets.
- Altered Hsp90 function in cancer: a unique therapeutic opportunity.
- HSP90 and the chaperoning of cancer.
- The stress response: implications for the clinical development of hsp90 inhibitors.
- Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration.
- Inhibition of oncogene expression using vector-generated RNA antisense.
- Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity.
- Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo.
- Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediat...
- Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.
- Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells.
- Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
- Hsp90: an emerging target for breast cancer therapy.
- Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
- 17AAG: low target binding affinity and potent cell activity--finding an explanation.
- Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.
- Pre-conditioning of smooth muscle cells via induction of the heat shock response limits proliferation following mechanical injury.
- The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.
- Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice.
- Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.
- Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran ...
- Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
- Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
- Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
- Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans.
- Design of quinolinedione-based geldanamycin analogues.
Schools
Johns Hopkins University School of Medicine
Children39s Hospital Boston
NciPob
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Boston Children's Hospital -
Johns Hopkins University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Ziad Hemzawi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith R. Dveirin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brenda J. Wittman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emmanuel Katsanis, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kartik Krishnan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yi Zeng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin Andreansky, MD
This Doctor is OpenDoctor Recommended.
|